Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284983 | 1.00 | GSR (0.56) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| SCHEMBL30514395 | 1.00 | GSR (0.56) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| SCHEMBL288798 | 0.98 | GSR (0.54) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| SCHEMBL60354 | 0.93 | GSR (0.46) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| SCHEMBL159650 | 0.93 | GSR (0.46) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| SCHEMBL288689 | 0.93 | GSR (0.46) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| SCHEMBL562061 | 0.93 | GSR (0.46) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| Hydrochloric Acid SCHEMBL31510869 | 0.91 | GSR (0.45) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| Ammonia Solution, Strong SCHEMBL8677036 | 0.91 | GSR (0.45) | GSRRNPEPCYP2D6NFKB1ENPEP | |
| Propionic Acid SCHEMBL29234998 | 0.85 | S1PR2 (0.45) | GSRCYP2D6NFKB1ENPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | PFIZER INC. | 2003-03-20 | — | — | US | claimed |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | LINDE ROBERT G (US) | 2002-02-07 | — | — | US | claimed |
| EP-1113008-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| US-4518532-A | ANTITIMOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-05-21 | — | — | US | disclosed |
| US-4430346-A | N-(4-(3-AMINOPROPYL)AMINOBUTYL)-2-(CS)-7-GUANIDINO-3 -HYDROXYHEPTANAMIDE)-2-HYDROXYETHANAMIDE, ESTERS, AMIDATION ACID CATALYST | BRISTOL-MYERS COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | GSR 4536/4885RNPEP 39/4885CYP2D6 779/4885 |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | GSR 608/4885RNPEP 3072/4885CYP2D6 1244/4885 |
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | UMPS, UPP1, UGP2 | GSR 2888/4885RNPEP 2104/4885CYP2D6 33/4885 |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | UMPS, UPP1, NUDT1 | GSR 2726/4885RNPEP 2169/4885CYP2D6 42/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | GSR 3245/4885RNPEP 90/4885CYP2D6 616/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | GSR 4365/4885RNPEP 3661/4885CYP2D6 3327/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | GSR 2122/4885RNPEP 112/4885CYP2D6 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.